JP2021513355A5 - - Google Patents
Info
- Publication number
- JP2021513355A5 JP2021513355A5 JP2020543344A JP2020543344A JP2021513355A5 JP 2021513355 A5 JP2021513355 A5 JP 2021513355A5 JP 2020543344 A JP2020543344 A JP 2020543344A JP 2020543344 A JP2020543344 A JP 2020543344A JP 2021513355 A5 JP2021513355 A5 JP 2021513355A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cedna vector
- vector according
- nucleotide sequence
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024141968A JP2024167281A (ja) | 2018-02-14 | 2024-08-23 | 非ウイルス性ｄｎａベクター、ならびに抗体および融合タンパク質の産生のためのその使用 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862630670P | 2018-02-14 | 2018-02-14 | |
| US201862630676P | 2018-02-14 | 2018-02-14 | |
| US62/630,676 | 2018-02-14 | ||
| US62/630,670 | 2018-02-14 | ||
| US201862680087P | 2018-06-04 | 2018-06-04 | |
| US201862680092P | 2018-06-04 | 2018-06-04 | |
| US62/680,087 | 2018-06-04 | ||
| US62/680,092 | 2018-06-04 | ||
| PCT/US2019/018016 WO2019161059A1 (en) | 2018-02-14 | 2019-02-14 | Non-viral dna vectors and uses thereof for antibody and fusion protein production |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024141968A Division JP2024167281A (ja) | 2018-02-14 | 2024-08-23 | 非ウイルス性ｄｎａベクター、ならびに抗体および融合タンパク質の産生のためのその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021513355A JP2021513355A (ja) | 2021-05-27 |
| JP2021513355A5 true JP2021513355A5 (https=) | 2022-02-22 |
Family
ID=67619630
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543344A Pending JP2021513355A (ja) | 2018-02-14 | 2019-02-14 | 非ウイルス性ｄｎａベクター、ならびに抗体および融合タンパク質の産生のためのその使用 |
| JP2024141968A Pending JP2024167281A (ja) | 2018-02-14 | 2024-08-23 | 非ウイルス性ｄｎａベクター、ならびに抗体および融合タンパク質の産生のためのその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024141968A Pending JP2024167281A (ja) | 2018-02-14 | 2024-08-23 | 非ウイルス性ｄｎａベクター、ならびに抗体および融合タンパク質の産生のためのその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220042035A1 (https=) |
| EP (1) | EP3752191A4 (https=) |
| JP (2) | JP2021513355A (https=) |
| KR (1) | KR20200120649A (https=) |
| CN (1) | CN111818942A (https=) |
| AU (1) | AU2019221642A1 (https=) |
| BR (1) | BR112020016288A2 (https=) |
| CA (1) | CA3091250A1 (https=) |
| IL (1) | IL276469A (https=) |
| MA (1) | MA51842A (https=) |
| MX (1) | MX2020008470A (https=) |
| PH (1) | PH12020551039A1 (https=) |
| SG (1) | SG11202006431WA (https=) |
| WO (1) | WO2019161059A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ762100A (en) | 2017-08-09 | 2025-12-19 | Bioverativ Therapeutics Inc | Nucleic acid molecules and uses thereof |
| US12442015B2 (en) * | 2018-01-19 | 2025-10-14 | Generation Bio Co. | Closed-ended DNA vectors obtainable from cell-free synthesis and process for obtaining ceDNA vectors |
| EP3833766A1 (en) | 2018-08-09 | 2021-06-16 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof for non-viral gene therapy |
| WO2021046265A1 (en) * | 2019-09-06 | 2021-03-11 | Generation Bio Co. | Lipid nanoparticle compositions comprising closed-ended dna and cleavable lipids and methods of use thereof |
| WO2021169167A1 (en) * | 2020-02-29 | 2021-09-02 | Nanjing GenScript Biotech Co., Ltd. | Method for treating coronavirus infections |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| JP2023520763A (ja) * | 2020-03-24 | 2023-05-19 | ジェネレーション バイオ カンパニー | ゴーシェ治療薬を発現するための非ウイルス性ｄｎａベクター及びその使用 |
| JP2023535632A (ja) | 2020-07-27 | 2023-08-18 | アンジャリウム バイオサイエンシズ エージー | Ｄｎａ分子の組成物、その作製方法、及びその使用方法 |
| US20240066149A1 (en) * | 2021-01-12 | 2024-02-29 | Jcr Pharmaceuticals Co., Ltd. | Nucleic Acid Molecule Containing Incorporated Gene Encoding Fused Protein of Ligand and Protein Having Physiological Activity |
| CA3206107A1 (en) * | 2021-01-26 | 2022-08-04 | Brian Furmanski | Vector constructs for delivery of nucleic acids encoding therapeutic anti-tnf antibodies and methods of using the same |
| AU2022264509A1 (en) * | 2021-04-27 | 2023-12-14 | Generation Bio Co. | Non-viral dna vectors expressing therapeutic antibodies and uses thereof |
| CA3218126A1 (en) * | 2021-05-07 | 2022-11-10 | Matthew MANGANIELLO | Lyophilized non-viral dna vector compositions and uses thereof |
| WO2023091708A1 (en) * | 2021-11-18 | 2023-05-25 | The Brigham And Women's Hospital, Inc. | Induced proteinopathy models |
| CN120282800A (zh) * | 2022-12-12 | 2025-07-08 | 苏州荷光科汇生物科技有限公司 | 一种感染视网膜的aav载体、阿达木单抗及其应用 |
| US11993783B1 (en) * | 2023-03-27 | 2024-05-28 | Genecraft Inc. | Nucleic acid molecule comprising asymmetrically modified ITR for improving expression rate of inserted gene, and use thereof |
| CN116549632B (zh) * | 2023-03-28 | 2024-09-10 | 中国人民解放军军事科学院军事医学研究院 | 抗Lingo-1抗体Opicinumab的新用途及针对新用途的药物 |
| EP4713372A1 (en) * | 2023-05-15 | 2026-03-25 | Immunecare Biopharmaceuticals (Shanghai) Co., Ltd | Recombinant fusion protein for treatment of pulmonary hypertension |
| WO2025092951A1 (en) * | 2023-11-03 | 2025-05-08 | Shanghai Vitalgen Biopharma Co., Ltd. | Recombinant adeno-associated viral vectors for treating fabry disease |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE318923T1 (de) * | 2000-06-01 | 2006-03-15 | Univ North Carolina | Doppelsträngige parvovirus-vektoren |
| CN100513414C (zh) * | 2001-08-27 | 2009-07-15 | 杰南技术公司 | 进行抗体表达和装配的系统 |
| GB0903207D0 (en) * | 2009-02-25 | 2009-04-08 | Ucb Pharma Sa | Method for expressing multimeric proteins |
| US8865881B2 (en) * | 2011-02-22 | 2014-10-21 | California Institute Of Technology | Delivery of proteins using adeno-associated virus (AAV) vectors |
| EP2500434A1 (en) * | 2011-03-12 | 2012-09-19 | Association Institut de Myologie | Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery |
| WO2014143932A1 (en) * | 2013-03-15 | 2014-09-18 | The University Of North Carolina At Chapel Hill | Synthetic adeno-associated virus inverted terminal repeats |
| BR112016017817A2 (pt) * | 2014-02-06 | 2017-10-10 | Genzyme Corp | composições e métodos para o tratamento e a prevenção de degeneração macular |
| EP3151866B1 (en) * | 2014-06-09 | 2023-03-08 | Voyager Therapeutics, Inc. | Chimeric capsids |
| MX2018010633A (es) * | 2016-03-03 | 2019-06-13 | Univ Massachusetts | Acido desoxirribonucleico (adn) lineal duplex de extremos cerrados para transferencia genica no viral. |
| US11549125B2 (en) * | 2017-08-09 | 2023-01-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Closed-ended, linear, duplex adenoassociated virus DNA, and uses thereof |
| KR102696307B1 (ko) * | 2017-09-08 | 2024-08-16 | 제너레이션 바이오 컴퍼니 | 비-바이러스성 캡시드-비함유 dna 벡터의 지질 나노입자 제형 |
| CA3075168A1 (en) * | 2017-09-08 | 2019-03-14 | Generation Bio Co. | Modified closed-ended dna (cedna) |
| MX2020003888A (es) * | 2017-10-18 | 2020-11-06 | Regenxbio Inc | Anticuerpos terapeuticos postraduccionalmente modificados completamente humanos. |
| CA3084185A1 (en) * | 2017-12-06 | 2019-06-13 | Generation Bio Co. | Gene editing using a modified closed-ended dna (cedna) |
| US12442015B2 (en) * | 2018-01-19 | 2025-10-14 | Generation Bio Co. | Closed-ended DNA vectors obtainable from cell-free synthesis and process for obtaining ceDNA vectors |
| MA52116A (fr) * | 2018-03-02 | 2021-01-06 | Generation Bio Co | Vecteurs d'adn à extrémité fermée (cedna) pour l'insertion de transgènes au niveau de havres génomiques sécuritaires (gsh) dans des génomes humains et murins |
-
2019
- 2019-02-14 KR KR1020207024274A patent/KR20200120649A/ko not_active Ceased
- 2019-02-14 EP EP19753655.0A patent/EP3752191A4/en active Pending
- 2019-02-14 CN CN201980013028.XA patent/CN111818942A/zh active Pending
- 2019-02-14 WO PCT/US2019/018016 patent/WO2019161059A1/en not_active Ceased
- 2019-02-14 JP JP2020543344A patent/JP2021513355A/ja active Pending
- 2019-02-14 SG SG11202006431WA patent/SG11202006431WA/en unknown
- 2019-02-14 MA MA051842A patent/MA51842A/fr unknown
- 2019-02-14 BR BR112020016288-4A patent/BR112020016288A2/pt unknown
- 2019-02-14 US US16/968,990 patent/US20220042035A1/en not_active Abandoned
- 2019-02-14 AU AU2019221642A patent/AU2019221642A1/en not_active Abandoned
- 2019-02-14 CA CA3091250A patent/CA3091250A1/en active Pending
- 2019-02-14 MX MX2020008470A patent/MX2020008470A/es unknown
-
2020
- 2020-07-03 PH PH12020551039A patent/PH12020551039A1/en unknown
- 2020-08-03 IL IL276469A patent/IL276469A/en unknown
-
2024
- 2024-08-23 JP JP2024141968A patent/JP2024167281A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021513355A5 (https=) | ||
| US20210324343A1 (en) | Recombinant adeno-associated virus particle purification comprising an affinity purification step | |
| AU2018291023B2 (en) | AAV vector column purification methods | |
| JP2021513999A5 (https=) | ||
| JP2022033855A5 (https=) | ||
| CA2379564C (en) | Structural protein of adeno-associated virus with modified chromatographic properties, its production and use | |
| JP2018526003A (ja) | イヌの癌を治療するためのキメラａａｖ−抗ｖｅｇｆ | |
| JP2008506389A (ja) | Ａａｖベクター組成物および免疫グロブリンの発現の増強のための方法ならびにその使用方法 | |
| JP2022524434A5 (https=) | ||
| RU2014146159A (ru) | Композиция и способы высокоэффективного переноса генов с помощью вариантов капсида aav | |
| JP2022523679A5 (https=) | ||
| JP2022520803A5 (https=) | ||
| Demircan et al. | T-cell specific in vivo gene delivery with DART-AAVs targeted to CD8 | |
| JP2017506230A5 (https=) | ||
| CA3129506A1 (en) | Cancer-targeted, virus-encoded, regulatable t (catvert) or nk cell (catvern) linkers | |
| RU2016135771A (ru) | Композиции и способы лечения и предотвращения дегенерации желтого пятна | |
| JP2023520763A5 (https=) | ||
| JP2024509251A5 (https=) | ||
| AR123948A1 (es) | ANTICUERPOS ANTI-TNF-a VECTORIZADOS PARA INDICACIONES OCULARES | |
| JP2021511020A5 (https=) | ||
| Youjin et al. | The treatment of hemophilia A: from protein replacement to AAV-mediated gene therapy | |
| US20240050476A1 (en) | Combination of deoxyribonuclease enzyme and cell therapies for treatment of cancer | |
| JP2023504201A5 (https=) | ||
| McConnell et al. | Generation Of Potent And High-Yield Exosome-Associated AAV (exoAAV) Using Engineered Exosomes | |
| CA2975569C (en) | Recombinant adeno-associated virus particle purification comprising an affinity purification step |